BioCardia scuttles IPO; Dauntless Pharma raises $12M A round;

@FierceBiotech: ICYMI: 'Cures' bill, designed to speed drug approvals, could be too much of a good thing, dissenters say. Story | Follow @FierceBiotech

@JohnCFierce: Schoenebaum sees great stuff in $BIIB data, predicts a rise in share price. | Follow @JohnCFierce

@DamianFierce: $BIIB investigator declined to color in 54-week 6mg data with my pen but agreed there should be a lottery. Image | Follow @DamianFierce

> Not everyone in biotechnology is finding fame and fortune on Wall Street. Gene therapy player BioCardia failed to float its IPO, deciding to postpone the offering to a later date. Story

> San Diego-based Dauntless Pharmaceuticals has launched with a $12 million round backed by CEO Joel Martin and Sofinnova. The money will be used to advance DP1038, a preclinical-stage drug for endocrine cancers. Release

> The UK's Oxford Nanopore Technologies raised $109 million. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Implanting a titanium tube inside damaged bones improves procedure to ward off amputations. Story | Follow @FierceMedDev

@EmilyWFierce: A U.K. research firm is developing tech to make diagnostic tests with an inkjet printer. More from the BBJ | Follow @EmilyWFierce

> iHealth expands its retail, connected medical device empire and looks to move into corporations, hospitals. Article

> Propeller Health receives FDA clearance to sell its app and sensor to patients using Glaxo's inhalers. More

> Bloomberg: St. Jude Medical discussing takeover of Thoratec. Report

Pharma News

@FiercePharma: Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar. FiercePharmaMarketing report | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Horizon hikes Depomed offer to $2B in bid for 'friendly' deal talks. Report | Follow @CarlyHFierce

> Drugmakers like Gilead, Mylan and Novo, not Big Pharma, are job creators. More

> Should J&J break up? Get ready for a new round of debate. Story

Biotech Research News

> Meta-analysis: Avandia's impact on Parkinson's should spur new research. Report

> Animal study highlights role of mast cells in chronic eye diseases. More

> Specialized cells in Alzheimer's could be used for diagnosis, drugs. Report

> Yale scientists highlight a promising eczema study for Pfizer's Xeljanz. Story

> NYU Langone team spotlights new antibodies for Alzheimer's, Parkinson's. Article

Diagnostics News

> Illumina launches new lab service for HiSeq X sequencing systems. More

> Alere revs up engine with new deals and win for quick strep test. Story

> Exact Sciences reveals $179M public offering amid slumping Q2 sales. News

> Oxford Nanopore reels in $109M to ramp up R&D. Item

> Theranos inks Medicaid deal and snags CLIA waiver to expand Dx reach. Article

Pharma Marketing News

> Will Genzyme's Fabry pill only steal sales from Fabrazyme? Not if it acts like Cerdelga. More

> Abbott boosts generic drug sales by 31% in strong Q2 showing. Item

> Sanofi Pasteur drafts Bollywood star to talk up flu shots in India. Report

> What's in a pill color? Consumers see messages in red, blue, green and white. Story

> The PCSK9 countdown: Amgen's Repatha wins EU race, with Sanofi's Praluent up Friday at FDA. Article

Suggested Articles

IMV’s lead immunotherapy stopped ovarian cancer from getting worse in more than three-quarters of patients in a small phase 2 study.

The money will fund early-phase development of a CD47x4-1BB bispecific that Kahr plans to test with Roche’s checkpoint inhibitor Tecentriq.

Bicycle will apply its discovery platform to multiple targets, putting itself in a position to pull in up to $1.7 billion in milestones.